Early-Stage Esophageal Cancer Might Not Favor Endoscopic Resections
the Cancer Therapy Advisor take:
Patients with localized, early-stage esophageal cancer may undergo endoscopic esophageal resection, which uses a small camera attached to a flexible tube.
This instrument allows little to no distraction to the body while navigating to specific locations throughout the gastrointestinal tract. The surgeon then carries out an esophageal surgical resection to remove a small section of the patient’s esophagus and reconnect the remaining sections of the digestive tract.
Recently, there has been an increase of endoscopic resections over surgical resections; however, according to a study published in the Journal of the National Cancer Institute, an endoscopic resection may not be the best treatment for patients with localized, early-stage esophageal cancer. Senior author David J. Bentrem, MD, and researchers from Northwestern Medicine found that the more invasive, traditional surgical resection had an 87.6% 5-year survival rate, compared to the 76% 5-year survival rate for patients who underwent the less-invasive endoscopic resection.
Results indicated that esophageal resection increased for patients with T1a cancers from 19% in 2004 to 53% in 2010. For patients with T1b cancers, which are more mature and more likely to spread to at least one lymph node compared with T1a cancers, esophageal resection increased from 6.6% in 2004 to 20.9% in 2010.
A new study sheds light on the risks with the growing popularity of endoscopic resection.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Larotrectinib: Promising for All TRK-Positive Tumors
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy
- Modified XELIRI Yields Similar Outcomes to FOLFIRI in Metastatic CRC
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- NSCLC: Stratifying Patients With Complex EGFR Mutations